Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

CAPS Rating: 4 out of 5

A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs.

Results 1 - 20 of 68 : 1 2 3 4 Next »

Recs

0
Member Avatar AsianMatter (< 20) Submitted: 4/2/2014 9:17:58 PM : Outperform Start Price: $11.52 MNTA Score: -25.78

IZ

Recs

0
Member Avatar Kanga88 (24.13) Submitted: 2/25/2014 12:38:51 PM : Outperform Start Price: $17.51 MNTA Score: -56.55

The business proposition and execution of Momenta has been solid, and it is a matter of time that the company will emerge as an innovative leader in the 21st century pharmaceutical industry. Born in the biotech labs of MIT, MNTA has been developing and accumulating advanced proprietary technology which allows it to produce generic drugs cheaper and hopefully purer than the originals. This will allow it to play leadership roles in the US where costs of medicine should account for 10% or so of the running away health costs!
As a bonus, it also has invested in R&D platforms for discovering new drugs, hopefully with breakthroughs in the future too.

Its path to successful commercializations has been full of obstacles, including legal challenges and competitive pressures. But only patient long term investors should invest in biotech stocks-- Caveat emptor !

Recs

0
Member Avatar manirg (< 20) Submitted: 12/24/2013 10:28:22 AM : Outperform Start Price: $17.71 MNTA Score: -58.51

great potential , very undervalued

Recs

0
Member Avatar rknapton (63.67) Submitted: 8/22/2013 4:35:38 PM : Underperform Start Price: $14.90 MNTA Score: +59.31

Short. Pharma company whose revenues are getting slaughtered.

Recs

0
Member Avatar bclear2 (< 20) Submitted: 5/6/2013 3:16:55 AM : Outperform Start Price: $11.27 MNTA Score: -42.56

buying opportunity for a company that has developed a novel platform that greatly speeds the development and characterization of complex biological compounds.

Recs

0
Member Avatar solanZRaider (< 20) Submitted: 4/27/2013 12:48:14 AM : Outperform Start Price: $12.87 MNTA Score: -55.34

z

Recs

0
Member Avatar jimmers42 (< 20) Submitted: 10/5/2011 10:09:12 PM : Outperform Start Price: $12.13 MNTA Score: -100.98

innovation and patents will carry this one along way...potential buyout if patents hold up.

Recs

0
Member Avatar airheadmw (< 20) Submitted: 9/20/2011 7:03:46 PM : Outperform Start Price: $11.61 MNTA Score: -88.69

We still have time!

Recs

1
Member Avatar anchor68 (30.64) Submitted: 9/15/2011 8:09:04 PM : Outperform Start Price: $17.70 MNTA Score: -115.47

One word says it all: Generics- People not only want Affordable medications, they Demand it!!!

Recs

1
Member Avatar mikephilipsoh (< 20) Submitted: 6/8/2011 4:45:16 PM : Outperform Start Price: $19.48 MNTA Score: -110.56

This company has a number of drug candidates in its pipeline.

Recs

2
Member Avatar Blackarrow1969 (53.79) Submitted: 5/31/2011 10:58:42 AM : Outperform Start Price: $19.84 MNTA Score: -105.01

They're heavily into generic drugs, which should position them well in coming years.

Recs

1
Member Avatar KirkDCJ (< 20) Submitted: 2/23/2011 12:02:25 PM : Outperform Start Price: $13.20 MNTA Score: -84.97

Cheap at the price with room to run.

Recs

2
Member Avatar chimpcontest (< 20) Submitted: 2/21/2011 2:25:39 PM : Outperform Start Price: $13.45 MNTA Score: -83.39

nilesgold haiku

Lovenox sales are strong

Copaxone approval forthcoming

Short squeeze for the win

Recs

0
Member Avatar dgoldmeier (33.47) Submitted: 2/9/2011 5:22:29 PM : Outperform Start Price: $13.58 MNTA Score: -85.85

becoming a cash cow. MNTA is undervalued even if Teva started selling Lovenox tomorrow. The future looks good by developing drugs with high revenue and mad growth.

Recs

1
Member Avatar efarev (97.24) Submitted: 10/28/2010 5:01:50 AM : Outperform Start Price: $12.83 MNTA Score: -105.87

I like the risk reward, potential catalysts:
-m-enox = blockbuster
-t-enox will likely never see approval in US
-Teva is worried about copoxane for a good reason
-possibility of Novartis buyout
-robust biosimilar pipeline

There are plenty of risks as well, such as a negative copoxane decision, t-enox approval miracle, FDA biosimilar roadblocks, but they are pretty well priced in at this point.

Recs

0
Member Avatar lting77 (70.20) Submitted: 10/27/2010 10:13:57 PM : Outperform Start Price: $16.08 MNTA Score: -113.21

able to secure patents to prevent teva encroachment into the biologic arena, novartis tend to buy out their partners, m118 quietly in phase 3 trial

Recs

0
Member Avatar StonedToTheBone (< 20) Submitted: 9/24/2010 12:12:31 PM : Outperform Start Price: $14.64 MNTA Score: -114.16

zzlangerhans sold me

Recs

0
Member Avatar phils3 (< 20) Submitted: 8/31/2010 1:25:06 PM : Outperform Start Price: $14.69 MNTA Score: -129.35

Current stock price is insane. It is barely above where it traded before getting approval for generic Lovenox. Odds are very much in favor of also getting approval for generic Copaxone. Odds of Sanofi prevailing in their suit vs. the FDA are slim. The expected result of either of these 2 events, or a good earnings report, or any combination of the 3 should be an excellent catalyst to move this much higher.

Recs

0
Member Avatar jmbring (< 20) Submitted: 8/5/2010 11:21:59 AM : Outperform Start Price: $18.05 MNTA Score: -129.83

not sure of where MNTA is going near-term, but odds are decent it's well under-valued in the long run.

Recs

0
Member Avatar lagunabb (25.62) Submitted: 8/3/2010 10:03:28 AM : Outperform Start Price: $18.45 MNTA Score: -131.51

FDA clearance pending. Undervalued pipeline.

Results 1 - 20 of 68 : 1 2 3 4 Next »

Featured Broker Partners